SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Director/PDMR Shareholding

8 Mar 2017 07:00

RNS Number : 8101Y
Collagen Solutions PLC
08 March 2017
 

 

Collagen Solutions plc

("Collagen Solutions", the "Company" or the "Group")

 

8 March 2017

Grant of Options

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that options over 500,000 ordinary shares of 1p each in the Company ("Ordinary Shares") were granted on 7 March 2017 to Bradley Selman, VP Global Sales & Marketing ("Options").

 

The Options have an exercise period of ten years from grant and have an exercise price per Option of 5.75p. The Options vest in full upon the closing middle market price per Ordinary Share exceeding 27p or EPS for the relevant financial year achieving 1p during the exercise period.

 

- Ends -

 

Enquiries:

 

Collagen Solutions Plc

Contact via Walbrook

Jamal Rushdy, Chief Executive Officer

Gill Black, Chief Financial Officer

Cenkos Securities plc (Nominated Adviser and Broker)

Stephen Keys

Steve Cox

Callum Davidson

Tel: 0207 397 8900

 

 

Walbrook PR

Tel: 020 7933 8780 or collagen@walbrookpr.com

Mike Wort

Mob: 07900 608 002

Anna Dunphy

Mob: 07876 741 001

 

 

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Bradley Selman

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR (VP - Global Sales & Marketing - Executive Team Member)

b)

 

Initial notification /Amendment

 

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Collagen Solutions Plc

 

b)

 

LEI

 

 

N/A

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 

Identification code

 

 

Option to acquire 1p ordinary shares in Collagen Solutions Plc

 

N/A

 

b)

 

Nature of the transaction

 

 

Grant of Options

c)

 

Price(s) and volume(s)

 

 

Price (exercise): 5.75p

Volume(s): 500,000

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

N/A

 

N/A

 

e)

 

Date of the transaction

 

 

7 March 2017

f)

 

Place of the transaction

 

 

Outside a trading venue

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHOKFDNPBKKCNK
Date   Source Headline
20th Feb 20197:00 amRNSSale of Strategic Investment in Jellagen
18th Feb 20197:00 amRNSPresenting at the Hardman Investor Forum
4th Feb 20193:55 pmRNSVisit from Member of Scottish Parliament
31st Jan 20197:00 amRNSChondroMimetic® Update
16th Jan 20194:52 pmRNSDirector/PDMR Shareholding
15th Jan 20197:00 amRNSNew Manufacturing Agreement
7th Jan 20193:45 pmRNSAward of £1.54 million Scottish Enterprise Grant
4th Dec 20187:00 amRNSHalf-year Report
7th Nov 20187:00 amRNSInvestor presentation
5th Nov 20187:00 amRNSRealignment of Bond Repayments
23rd Oct 20187:00 amRNSTrading Update and Notice of Results
18th Oct 20187:00 amRNSBiotech and Money's Inve$tival Showcase
26th Sep 20185:04 pmRNSHolding(s) in Company
25th Sep 20183:05 pmRNSDirector/PDMR Shareholding
19th Sep 20185:01 pmRNSDirector/PDMR Shareholding
3rd Sep 201812:20 pmRNSDirector/PDMR Shareholding
3rd Sep 20187:00 amRNSBoard Appointments
3rd Sep 20187:00 amRNSExecutive Share Options Alignment
24th Aug 201811:47 amRNSDirector/PDMR Shareholding
22nd Aug 201811:40 amRNSResult of AGM
22nd Aug 20187:00 amRNSAGM Statement
21st Aug 20187:00 amRNSAppointment of Distributors in China
25th Jul 20185:21 pmRNSPosting of Annual Report and Notice of AGM
10th Jul 20187:00 amRNSFinal Results
13th Jun 20187:00 amRNSNotice of Results
8th May 20187:00 amRNSExhibiting at 18th ESSKA conference
3rd May 20183:27 pmRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSDirector/PDMR Shareholding
10th Apr 20187:00 amRNSAppointment of Chief Business Officer
6th Apr 20189:31 amRNSDirector/PDMR Shareholding
4th Apr 20187:00 amRNSTrading update
28th Mar 20187:00 amRNSProposed restructuring of New Zealand operations
1st Mar 20187:00 amRNSConference attendance
26th Feb 20187:15 amRNSHardman & Co: Nearing first proprietary product
22nd Feb 20181:00 pmRNSDirector/PDMR Shareholding
21st Feb 20187:00 amRNSPositive results of ChondroMimetic Clinical Study
15th Feb 20187:00 amRNSChina update
6th Feb 20187:00 amRNSInvestor presentation
20th Dec 201711:55 amRNSChondroMimetic® Update
19th Dec 20173:49 pmRNSHardman Research: Targeting long-term growth
18th Dec 20177:00 amRNSDirectorate Change
14th Dec 20177:00 amRNSAppointment of Chief Financial Officer
5th Dec 20177:00 amRNSHalf-year Report
27th Nov 20174:41 pmRNSSecond Price Monitoring Extn
27th Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20177:00 amRNSTrading update and notice of results
21st Sep 20171:28 pmRNSHardman Research: Engineering towards CE Mark
21st Sep 20177:00 amRNSStudy Update Patient Assessments Completed
18th Sep 20177:00 amRNSPresenting at the Hardman Investor Forum
12th Sep 20177:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.